Craniopharyngioma: Complications and Treatment

Overview

• Adamantinomatous (90%): more common in children; mixed solid/cystic with calcifications; CTNNB1 (beta-catenin) mutations (~94%)
• Papillary (10%): predominant in adults; mostly solid, rarely calcified; BRAF V600E mutations (~95%)

Imaging

Complications

Tumor-Related Complications

Post-Treatment Complications

• Complete panhypopituitarism and diabetes insipidus
• Severe hypothalamic obesity (damage to thirst, temperature, and appetite regulatory centers)
• Permanent neuroendocrine deficits requiring lifelong hormone replacement

• Cognitive and endocrine deficits
• Optic neuropathy
• Secondary malignancies
• Vascular injury - moyamoya disease

Treatment

1. Surgery (Primary Treatment)

• Transsphenoidal (preferred when hypothalamus is not involved; also for subdiaphragmatic tumors)
• Transcranial (subfrontal or pterional) for larger/suprasellar extension
• Endoscopic endonasal surgery (EES) - increasingly used; can be employed regardless of size/location except purely intraventricular tumors

• After total resection: ~30%
• After subtotal resection: ~57%
• After subtotal resection + radiation: ~30%

2. Radiation Therapy

• External beam radiotherapy (EBRT): Extends progression-free survival (PFS) after incomplete resection; used as primary treatment for unresectable or recurrent tumors
• Stereotactic radiosurgery (e.g., Gamma Knife): Used for small residual or recurrent disease
• Intracavitary irradiation: ³²P or ⁹⁰Y instilled into cystic components after stereotactic aspiration; suitable for purely cystic or mixed tumors

3. Intracystic Therapy (for Cystic Craniopharyngioma)

• Bleomycin (sclerosing agent) - risk of severe neurotoxicity if the cyst wall leaks into CSF
• Interferon-alpha - subcutaneous (short-acting or pegylated) or intracystic injection; shows promising results in delaying need for radiotherapy
• ³²P or ⁹⁰Y (radioactive colloids)

4. Targeted (Molecular) Therapy

• Papillary subtype (BRAF V600E): BRAF inhibitors (vemurafenib/dabrafenib) + MEK inhibitors have shown success in case reports and small series. A Phase II trial of combined MEK/BRAF inhibition is ongoing.
• Adamantinomatous subtype (CTNNB1/beta-catenin): Drugs targeting the Wnt/beta-catenin pathway are still under development.

5. Hormone Replacement

• GH, thyroid hormone, cortisol (ACTH axis), sex steroids, vasopressin (DI)
• Monitoring and treatment of hypothalamic obesity

Prognosis

Post-Craniotomy Hyponatremia After Hypernatremia in Craniopharyngioma

The Triphasic Response: Pathophysiology

Phase 1 - Diabetes Insipidus (Hypernatremia) - Hours to Days

• Mechanism: Axon shock following stalk transection. The severed axons cannot transmit signals from the hypothalamus to the posterior pituitary, so AVP secretion ceases.
• Result: Massive polyuria (hypotonic urine), hypernatremia, hypernatremia, rising serum osmolality.
• Duration: Several hours to a few days.

Phase 2 - SIADH (Hyponatremia) - Days 2 to 14

• Mechanism: The disconnected posterior pituitary gland (and the remaining severed axon terminals) undergoes Wallerian-type degeneration. As the axon terminals die, they dump all stored AVP uncontrollably into the bloodstream. This AVP release is completely autonomous - it is not regulated by osmolality or volume status.
• Result: Concentrated urine, free water retention, dilutional hyponatremia.
• Critical trap: Overly aggressive fluid administration during Phase 1 (to treat DI/hypernatremia) does NOT suppress this uncontrolled AVP release and can worsen the degree of dilutional hyponatremia in Phase 2.
• Duration: 2 to 14 days (until posterior pituitary AVP stores are depleted).

Phase 3 - Return of Permanent DI - After Day 10-14

• Mechanism: Once all stored AVP in the degenerating posterior pituitary is exhausted, DI returns - this time permanently, because >80-90% of the hypothalamic AVP neuronal cell bodies have undergone retrograde degeneration.
• Result: Polyuria resumes, permanent diabetes insipidus requiring lifelong desmopressin.

"Overly aggressive administration of fluids during the second phase does not suppress the uncontrolled vasopressin release from the damaged neurohypophysis and can lead to hyponatremia." - Goldman-Cecil Medicine

Isolated Second Phase (Without Phase 1 DI)

Clinical Data in Pediatric Craniopharyngioma

• 65.4% (17/26) had the full triphasic pattern: initial DI followed by hyponatremia days later
• 30.8% (8/26) had isolated persistent DI
• Triphasic response was significantly associated with higher Puget MRI classification (grades 1 and 2, indicating greater hypothalamic involvement)
• Dysnatremia was described as the most common and difficult-to-manage immediate post-operative complication

Differential Diagnosis of Post-Craniotomy Hyponatremia

"SIADH is treated by free-water restriction, whereas cerebral salt wasting is treated with volume repletion and sodium administration... Urine electrolyte analysis is not discriminative, as urine sodium is high in both disorders." - Barash's Clinical Anesthesia

Management of Phase 2 Hyponatremia

During the Transition (Phase 1 → Phase 2)

• Watch for abrupt cessation of polyuria - this signals the onset of Phase 2 AVP release
• Reduce or stop free water and hypotonic fluid administration immediately
• Do not reflexively give more fluids because urine output drops

Treating the Hyponatremia

1. Fluid restriction is the mainstay (euvolemic/hypervolemic SIADH)
2. Avoid over-correction - correction of hyponatremia must not exceed 8-10 mEq/L per 24 hours to prevent osmotic demyelination syndrome (central pontine myelinolysis), especially if hyponatremia is chronic or symptomatic
3. For severe symptomatic hyponatremia (seizures, altered consciousness): hypertonic saline (3% NaCl) can be given cautiously at controlled rates
4. Rule out concurrent adrenal insufficiency (common post-craniopharyngioma surgery given panhypopituitarism) - glucocorticoid deficiency independently causes hyponatremia and should be corrected with hydrocortisone

Monitoring

• Serum sodium every 4-6 hours in the acute post-operative phase
• Strict urine output monitoring - the shift from high to low output marks the phase transition
• After Day 14, anticipate return of DI and resume desmopressin

Avoiding the Trap

Summary Timeline

Surgery
   |
   ├── Hours 0–48: Phase 1 - DI → HYPERNATREMIA (polyuria, high serum Na+)
   |       ↓ Axon shock, no AVP release
   |
   ├── Days 2–14: Phase 2 - SIADH → HYPONATREMIA (oliguria, low serum Na+)
   |       ↓ Uncontrolled AVP dump from degenerating posterior pituitary
   |       ↓ *** Fluid restriction; avoid overcorrection ***
   |
   └── After Day 10–14: Phase 3 - Permanent DI returns
           ↓ AVP stores exhausted; retrograde neuronal degeneration
           ↓ Lifelong desmopressin required